Literature DB >> 9658364

The reliability and validity of the subjective peripheral neuropathy screen.

J H McArthur1.   

Abstract

Painful sensory neuropathy (PSN) is the most common neurological disorder associated with HIV infection and affects up to 30% of HIV-positive individuals. PSN may develop as a consequence of HIV infection or from the toxic effect of the antiretrovirals. Although several tools have been developed to screen for PSN, their validity and reliability has yet to be established among HIV-positive patients. The Subjective Peripheral Neuropathy Screen (SPNS) is a brief self-report tool that is currently being administered in the AIDS Clinical Trials Group. The objective of this study was to establish the psychometric properties of the SPNS screening tool for the correct identification of PSN in HIV-positive individuals. Specifically the goals were to determine the reliability, the validity, and the diagnostic efficiency of the SPNS in the detection of PSN. Data were abstracted on subjects enrolled in an ongoing natural history cohort. The SPNS was administered to a convenience sample of 39 HIV-positive individuals with PSN and 44 HIV-positive controls. Results showed the SPNS to be internally consistent (Cronbach's alpha = .86). SPNS score differences assessed by t-test were significantly different for individual symptoms of parasthesias, numbness, and pain of the lower extremities, and for severity measures (the Clinical Severity Grade, and the Average Severity Score) between the HIV-positive groups (p < .05). Using Spearman's rank, significant correlations were demonstrated between the neurological exam and the Clinical Severity Grade and the Average Severity Score, the neurological exam and vibratory quantitative sensory testing (QST) only, and the severity measures and vibratory QST only. Sensitivity and specificity analysis demonstrated that numbness of the lower extremities was the symptom with the highest efficiency for correctly classifying PSN. Thus, internal consistency, construct validity, and criterion related validity were confirmed with the SPNS for the correct classification of PSN in HIV-positive individuals.

Entities:  

Mesh:

Year:  1998        PMID: 9658364     DOI: 10.1016/S1055-3290(98)80048-4

Source DB:  PubMed          Journal:  J Assoc Nurses AIDS Care        ISSN: 1055-3290            Impact factor:   1.354


  15 in total

Review 1.  A Review of HIV-Specific Patient-Reported Outcome Measures.

Authors:  Kim Engler; David Lessard; Bertrand Lebouché
Journal:  Patient       Date:  2017-04       Impact factor: 3.883

2.  Dissociable Contributions of Precuneus and Cerebellum to Subjective and Objective Neuropathy in HIV.

Authors:  Natalie M Zahr; Kilian M Pohl; Adolf Pfefferbaum; Edith V Sullivan
Journal:  J Neuroimmune Pharmacol       Date:  2019-02-11       Impact factor: 4.147

3.  Assessment and Management of HIV Distal Sensory Peripheral Neuropathy: Understanding the Symptoms.

Authors:  Joyce K Anastasi; Anna M Pakhomova
Journal:  J Nurse Pract       Date:  2020-03-20       Impact factor: 0.767

4.  Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.

Authors:  W Iris Zhi; Patricia Chen; Alice Kwon; Connie Chen; Steven E Harte; Lauren Piulson; Susan Li; Sujata Patil; Jun J Mao; Ting Bao
Journal:  Breast Cancer Res Treat       Date:  2019-08-27       Impact factor: 4.872

5.  Acupuncture/Moxibustion RCT for Distal Sensory Peripheral Neuropathy in HIV/AIDS: Rationale, Design, Methods, Procedure and Logistics.

Authors:  Joyce K Anastasi; Bernadette Capili; Ann M Chung; Richard Hammerschlag
Journal:  EJOM       Date:  2010

6.  Acu/Moxa for distal sensory peripheral neuropathy in HIV: a randomized control pilot study.

Authors:  Joyce K Anastasi; Bernadette Capili; Donald J McMahon; Colin Scully
Journal:  J Assoc Nurses AIDS Care       Date:  2013 May-Jun       Impact factor: 1.354

Review 7.  Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy.

Authors:  Jennifer S Gewandter; Laurie Burke; Guido Cavaletti; Robert H Dworkin; Christopher Gibbons; Tony D Gover; David N Herrmann; Justin C Mcarthur; Michael P McDermott; Bob A Rappaport; Bryce B Reeve; James W Russell; A Gordon Smith; Shannon M Smith; Dennis C Turk; Aaron I Vinik; Roy Freeman
Journal:  Muscle Nerve       Date:  2016-12-23       Impact factor: 3.217

8.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

Authors:  Myungsun Lee; Jongseok Lee; Matthew W Carroll; Hongjo Choi; Seonyeong Min; Taeksun Song; Laura E Via; Lisa C Goldfeder; Eunhwa Kang; Boyoung Jin; Hyeeun Park; Hyunkyung Kwak; Hyunchul Kim; Han-Seung Jeon; Ina Jeong; Joon Sung Joh; Ray Y Chen; Kenneth N Olivier; Pamela A Shaw; Dean Follmann; Sun Dae Song; Jong-Koo Lee; Dukhyoung Lee; Cheon Tae Kim; Veronique Dartois; Seung-Kyu Park; Sang-Nae Cho; Clifton E Barry
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

9.  HIV Associated Sensory Neuropathy.

Authors:  Amruth G; Praveen-Kumar S; Nataraju B; Nagaraja Bs
Journal:  J Clin Diagn Res       Date:  2014-07-20

10.  Screening for HIV-associated peripheral neuropathy in resource-limited settings.

Authors:  Deanna Cettomai; Judith K Kwasa; Gretchen L Birbeck; Richard W Price; Craig R Cohen; Elizabeth A Bukusi; Caroline Kendi; Ana-Claire L Meyer
Journal:  Muscle Nerve       Date:  2013-08-27       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.